trending Market Intelligence /marketintelligence/en/news-insights/trending/4CuYzT8cCz6urVH3t4DIYQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Verona Pharma appoints chief medical officer

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Verona Pharma appoints chief medical officer

Verona Pharma PLC named Kathleen Rickard its chief medical officer, effective Feb. 1.

In her new role, Rickard will oversee development of Verona Pharma's drug RPL554, a maintenance treatment of chronic obstructive pulmonary disease, cystic fibrosis and possibly asthma.

Rickard has 25 years of experience in clinical research in respiratory medicine, Verona said in a news release. She was previously head of clinical development at Circassia Pharmaceuticals plc. She was also the chief medical officer at Sweden-based medical technology company Aerocrine AB.

London-based Verona Pharma develops and commercializes therapies for respiratory diseases with significant unmet medical needs.